OnKure Therapeutics, Inc.

The current price of OKUR is $2.87 — it has increased by 13.47% since the previous close. Data as of Nov 6, 2026.

OKUR is up 8.52% over the past week, up 21.91% over the past month and down 2.55% over the past year. The price is below its 200-day moving average of $3.60.

Analysts' average 12-month price target for OKUR is $14.00, which implies 388.66% upside from the current price. Individual estimates range from $14.00 to $14.00.

Of the 6 analysts covering OnKure Therapeutics, Inc., 5 rate it a buy and 1 rates it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

OnKure Therapeutics, Inc. has a market capitalization of $116.02M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

In its most recent quarterly report, OnKure Therapeutics, Inc. posted a loss of $0.36 per share against an estimate of -$0.4067, beating expectations by 11.48%. Upcoming reports are listed in the earnings calendar.

OnKure Therapeutics, Inc. has not paid any dividends over the past year.

Companies most comparable to OnKure Therapeutics, Inc. include Mersana Therapeutics, Inc., PDS Biotechnology Corporation, Xilio Therapeutics, Inc., Kezar Life Sciences, Inc. and Actinium Pharmaceuticals, Inc.

In the latest trading session OKUR moved between $2.31 and $2.88, a range of 19.72% of its current price.

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of OnKure Therapeutics, Inc. shows a buy rating today and a sell rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for OnKure Therapeutics, Inc. is sell. Technical ratings are indicators, not investment advice.

Over the past 52 weeks OKUR has traded between $2.01 and $5.38. The current price is 46.75% below its 52-week high.